Zydus Lifesciences Limited (ZYDUSLIFE) — Financial Results | 13 August 2025

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Zydus Lifesciences reported Q1 FY26 consolidated revenue from operations of ₹65,537 crores, with net profit after tax of ₹14,668 crores. Basic earnings per share stood at ₹14.58. The company maintained operational momentum with stable margins, though the filing provides limited year-over-year comparison data in the newspaper extract format.

📄 View Original Announcement (PDF)

About Zydus Lifesciences Limited (ZYDUSLIFE)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,01,800.69 Cr P/E: 22.5

View full ZYDUSLIFE stock details →

📡 Get AI alerts when ZYDUSLIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ZYDUSLIFE — Free

📊 More ZYDUSLIFE filings

See all ZYDUSLIFE filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ZYDUSLIFE files new disclosures

Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ZYDUSLIFE — Free

Free account · 2 AI queries/day